Comment on 'Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017'

Drug Saf. 2019 May;42(5):689-691. doi: 10.1007/s40264-019-00814-5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Europe
  • Ferric Compounds*
  • Iron*
  • Maltose / analogs & derivatives

Substances

  • Ferric Compounds
  • ferric carboxymaltose
  • Maltose
  • Iron